Inflammatory bowel disease (IBD) is a chronic nonspecific intestinal inflammatory disease of unknown etiology, mainly including ulcerative colitis (UC) and Crohn’s disease ( CD). The treatment landscape for IBD is rapidly expanding as new treatments continue to be developed.
A recent article published in Aliment Pharmacol Ther The current emerging drugs for the treatment of IBD have been sorted and summarized, come and collect them!
1Study ResultsIn the treatment of UC, S1P receptor modulators estrasimod, ozanimod, IL-23 monoclonal antibody mirikizumab, anti-lymphocyte migration drug ontamalimab, subcutaneous vedolizumab, JAK inhibitors upadacitinib, filgotinib and TLR9 agonist cobitolimod achieved Primary endpoint of Phase IIb and/or Phase III studies. In the treatment of CD, IL-23 monoclonal antibodies risankizumab, mirikizumab, guselkumab, JAK inhibitors upadacitinib, filgotinib and anti-lymphocyte migration drugs ontamalimab and etrolizumab achieved RC Tprimary endpoint.
2List of new drugs under investigation< p>Table 1: emerging drugs for IBD (Phase II/III studies)
>TNF (tumournecrosis factor), tumor necrosis factor; AS (ankylosingspondylitis), ankylosing spondylitis;CD( Crohn’sdisease), Crohn’s disease; IBD(inflammatorybowel disease< span>), inflammatory bowel disease; IL-23 (interleukin-23), interleukin< /span>-23;IV (intravenous), vein Injection; MAdCAM-1(mucosaladd ressin cell adhesion molecule-1), human mucosal addressin cell adhesion molecule-1; MS(multiplesclerosis), multiple sclerosis; OLE( open-labelextension), open-label extension; PA (psoriaticarthritis), silver Psoriatic arthritis; RA (rheumatoidarthritis), rheumatoid arthritis;SC(subcutaneous), subcutaneous injection; S1P( sphingosine-1phosphate), sphingosine–1-phosphate ;TLR-9 (Toll-like receptor 9), Toll span>-like receptor-9; UC (Ulcerative colitis ), ulcerative colitis
aby inviteRecruit
bdo not recruit
Table 2: New drugs for IBD in the early stage of development
img>AA3R (adenosine A3receptor), adenosine receptor A3; ARK (adrenergic receptor kinase), adrenergic receptor kinase; DHODH (dihydroorotate dehydrogenase), dihydroorotate dehydrogenase; IBD (inflammatory bowel disease), inflammatory bowel disease; IL (interleukin), interleukin; JAK (Janus kinase), Janus kinase; LANCL2 (lanthionine synthetase C-like 2), leukotriene synthetase C-like protein 2; LTA4H (leukotriene A4 hydrolase), leukotriene A4 hydrolase; NCT (National Clinical Trial); NKG2D (naturalkiller receptor group 2 member D); NSKI (narrow spectrum kinase inhibitor); PHD (prolyl hydroxylase inhibitor), prolyl hydroxylase HIF-1α (hypoxia-inducible factor 1 alpha), hypoxia-inducible factor 1α; S1P (sphingosine-1phosphate), sphingosine-1-phosphate; TL1A (tumournecrosis factor-like cytokine 1A); TNF (tumour necrosis factor), tumor necrosis factor; TPL2 (tumour progression locus 2); TYK (tyrosine kinase) tyrosine kinase
a< /span>Not currently recruitingbGIRestrictedcNot recruiteddRecruitment status unknown
3Summary
Among the emerging drugs for IBD, the results of early clinical trials of some drugs have shown positive efficacy and safety Data, another part of the treatment pipeline drugs. As more new drugs for CD and UC are approved for clinical use, more research is needed in the future to assess predictors of treatment response and conduct head-to-head trials to inform providers how to best position treatment options for patients with IBD .
